Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Glenmark Pharmaceuticals shares tumble nearly 6% over alleged false claims about ‘FabiFlu’

PTI
Updated: July 20th, 2020, 13:24 IST
in Business
0
FabiFlu
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

New Delhi: Shares of Glenmark Pharmaceuticals on Monday tumbled nearly 6 per cent after India’s drug regulator sought clarification from the company over its alleged “false claims” about the use of anti-viral FabiFlu on COVID-19 patients with comorbidities and also over the “pricing” of the drug.

The stock declined 5.10 per cent to Rs 408 on the BSE and at the NSE, it tanked 5.75 per cent to Rs 405.

Also Read

India, Canada conclude sixth round of talks for trade pact

13 hours ago

AI cannot take jobs of skilled workers: PM Modi

14 hours ago

The drug regulator has sought clarification from Glenmark Pharmaceuticals after receiving a complaint from a member of Parliament.

In a letter to the Mumbai-based company, Drugs Controller General of India (DCGI) Dr V G Somani stated that his office received a representation from an MP that the total cost of the treatment with FabiFlu (favipiravir) will be around Rs 12,500 and that the “cost proposed by Glenmark is definitely not in the interest of the poor, lower middle class and middle-class people of India.”

“Further it has been mentioned in the representation that Glenmark has also claimed that this drug is effective in co-morbid conditions like hypertension, diabetics, whereas in reality, as per protocol summary, this trial was not designed to assess the FabiFlu in comorbid condition,” the letter dated July 17 read.

No clinically sufficient data specific to these conditions are available, the DCGI said in its letter.

Glenmark Pharmaceuticals had on July 13 said it has cut the price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 by 27 per cent to Rs 75 per tablet.

The company had launched FabiFlu last month at a price of Rs 103 per tablet.

 

PTI

Tags: COVID drugDCGIFabiFluGlenmark Pharmaceuticalsshares
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Geetanjali Patro

December 12, 2019
#MyPaperBagChallenge

Mrutyunjaya Behera

December 12, 2019
#MyPaperBagChallenge

Vandana Singh

December 12, 2019
#MyPaperBagChallenge

Keshab Chandra Rout

December 12, 2019
#MyPaperBagChallenge

Priyabrata Mohanty

December 12, 2019
#MyPaperBagChallenge

Tabish Maaz

December 12, 2019
#MyPaperBagChallenge

Archana Parida

December 12, 2019
#MyPaperBagChallenge

Adyasha Priyadarsani Sendha

December 12, 2019
#MyPaperBagChallenge

Pratik Kumar

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Diptiranjan Biswal

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Sibarama Khotei

December 12, 2019
#MyPaperBagChallenge

Kamana Singh

December 12, 2019
#MyPaperBagChallenge

Anshuman Sahoo

December 12, 2019
#MyPaperBagChallenge

Archit Mohapatra

December 12, 2019
#MyPaperBagChallenge

Ipsita

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Faiza Firdous

December 12, 2019
#MyPaperBagChallenge

Sipra Mishra

December 12, 2019
#MyPaperBagChallenge

Priyasha Pradhan

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
#MyPaperBagChallenge

Anasuya Sahoo

December 12, 2019
#MyPaperBagChallenge

Arya Ayushman

December 12, 2019
#MyPaperBagChallenge

Rajashree Pravati Mohanty

December 12, 2019
#MyPaperBagChallenge

Lopali Pattnaik

December 12, 2019
#MyPaperBagChallenge

Pitabas Tripathy

December 12, 2019
#MyPaperBagChallenge

Praptimayee Biswal

December 12, 2019
#MyPaperBagChallenge

Mandakini Dakua

December 12, 2019
#MyPaperBagChallenge

Aishwarya Ranjan Mohanty

December 12, 2019

Archives

Editorial

Covert Shame

Aakar Patel
November 22, 2026

By Aakar Patel Murders committed by the state in India have a name: encounter. Those who carry them out are...

Read moreDetails

An Emerging Norm

November 21, 2026

By Dilip Cherian Mallika Srinivasan’s third consecutive one-year extension as chairperson of the Public Enterprises Selection Board (PESB) is increasingly...

Read moreDetails

Tech Terror

November 18, 2026

It cannot be a coincidence that when the world was still trying to come to terms with the prospect of...

Read moreDetails

More Miseries Ahead

Inflation in India
November 17, 2026

Life is getting difficult by the day for Indians with all us citizens reeling under the dual shocks of rising...

Read moreDetails
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2025 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2025 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2025 All rights Reserved by OrissaPOST